Asthma
Showing NaN - NaN of 192
Asthma Trial in Worldwide (BFF MDI 160/9.6 µg BID (320/19.2µg/day), BD MDI 160 µg BID (320 µg/day))
Recruiting
- Asthma
- BFF MDI 160/9.6 μg BID (320/19.2μg/day)
- BD MDI 160 μg BID (320 μg/day)
-
Huntington Beach, California
- +52 more
Mar 9, 2023
Asthma Trial in Worldwide (BGF MDI 320/28.8/9.6 µg, BGF MDI 320/14.4/9.6 µg, BFF MDI 320/9.6 µg)
Recruiting
- Asthma
- BGF MDI 320/28.8/9.6 μg
- +3 more
-
Muscle Shoals, Alabama
- +387 more
Jan 18, 2023
Asthma Trial in Worldwide (Tezepelumab)
Recruiting
- Asthma
- Tezepelumab
-
Newport Beach, California
- +102 more
Jan 11, 2023
Asthma Trial in London, Manchester (Human beta common receptor antagonist mAb, Placebo)
Recruiting
- Asthma
- Human beta common receptor antagonist monoclonal antibody
- Placebo
-
Berlin, Germany
- +2 more
Dec 21, 2022
Asthma Trial in Worldwide (MEDI3506, Placebo)
Active, not recruiting
- Asthma
- MEDI3506
- Placebo
-
Bakersfield, California
- +64 more
Dec 19, 2022
Observational Study of Obstructive Lung Disease (NOVELTY)
Active, not recruiting
- Asthma
- +2 more
- Blood draw
- +3 more
-
Loma Linda, California
- +302 more
Nov 22, 2022
Asthma Trial in Germany
Active, not recruiting
- Asthma
-
Aschaffenburg, Germany
- +51 more
Nov 3, 2022
Study on Patterns of Care in Mild Asthmatic Patients
Completed
- Asthma
-
Berlin, Germany
- +58 more
Sep 26, 2022
Asthma Trial in Berlin (Reminders and feedback to improve adherence, No reminders and feedback to improve adherence)
Recruiting
- Asthma
- Reminders and feedback to improve adherence
- No reminders and feedback to improve adherence
-
Berlin, GermanyMECS Research GmbH
Sep 21, 2022
Asthma, Severe Eosinophilic Asthma Trial in Worldwide (Symbicort®, Fasenra®, Ventolin®)
Active, not recruiting
- Asthma
- Severe Eosinophilic Asthma
- Symbicort®
- +2 more
-
Brest Cedex, France
- +22 more
Aug 24, 2022
Asthma Trial in Worldwide (BFF MDI 320/9.6 µg, BFF MDI 160/9.6 µg, BD MDI 320 µg)
Recruiting
- Asthma
- BFF MDI 320/9.6 μg
- +3 more
-
Saraland, Alabama
- +121 more
Aug 22, 2022
Inhalative Therapy in Real- Life Conditions
Active, not recruiting
- Asthma
- MF/IND/GLY plus sensor system
- FDC therapy
-
Ulm, BW, Germany
- +25 more
Aug 10, 2022
Chronic Rhinosinusitis With Nasal Polyps, Asthma Trial in Worldwide (Dupilumab, Omalizumab, Placebo)
Recruiting
- Chronic Rhinosinusitis With Nasal Polyps
- Asthma
- Dupilumab
- +2 more
-
Tucson, Arizona
- +65 more
Jul 12, 2022
Asthma Trial in Worldwide (dupilumab, Matching )
Recruiting
- Asthma
- dupilumab
- Matching placebo
-
Rolling Hills Estates, California
- +29 more
Mar 18, 2022